Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07543419
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.

Key Dates

First listed
Apr 21, 2026
Start date
Dec 17, 2025
Status verified
Jul 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
250 participants (estimated)

Primary Outcome Measure

Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) during the observational period. [ Time Frame: Baseline,6 months and 1 and 1,5 years after initiation of secukinumab ]

Central Contacts

Find similar trials

Nationwide
Hidradenitis suppurativa trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies